FULL-PROPOSAL APPLICATION FORM

This template is an indicative model of proposal application form. It includes the initial template of preproposals application form. The eligible pre-proposals and related contents will be made available for modification to each applicants invited to submit the full proposal at the STEP 2. Changes allowed in the online application form and in the project description document must be allowed by the relevant FPO in advance. Each proposal will be assessed against the compliance of such allowed changes as part of STEP 2 International Eligibility check. All proposals have to be submitted online via the Online submission tool. The format of the proposal application form will be adapted to fit the Online submission tool.

General quidance for all applicants:

- The proposal must be written in English;
- The different sections of the application should not exceed the prescribed maximum space;
- Any documents other than those requested as part of the proposal will not be forwarded to Evaluation Committee members.

Please make sure to respect the eligibility rules of the call.

Please also consult Funding Organisations' rules advertised in <u>Water4Al JTC2022 Call Announcement</u> which are compulsory. Applicants are strongly advised to contact their respective Funding Organisations (list available on Water4All website) and to confirm their eligibility with their Funding Organisations before submitting the proposal.

Applicants should note that information on the core data (e.g., funding requested or institutions) cannot be changed in full proposals, unless explicitly requested by evaluators, by a funding organisation or by the CSC. Please note that the information given in the pre-proposals is binding. No major changes regarding the proposals' content will be allowed by the Call Steering Committee (CSC) between the pre-proposals and full proposals.

Regarding the administrative details, a limited number of changes may be allowed, provided they are in line with the general rules of the call and the rules of the Funding Partner Organisations (FPO). Participant shall contact the call secretariat via e-mail and their FPO via the contacts reported in Annex C in order to inform them about their willingness to modify the project proposal. Requests for changes shall be assessed and allowed by the FPOs.

Minor change of budget must be allowed by the relevant FPO.

Changes in the consortium composition:

No changes of coordinator (i.e., Principal Investigator) will be allowed, except in case of force majeure. A request of change of coordinator must be submitted to the Call Secretariat, at least one week before the deadline for submitting full proposals and it will be discussed on a case-by-case basis by the CSC.

Changes in the consortium composition are allowed (maximum 2 changes of Project Partners in proposals with more than 5 partners; maximum 1 change of project partner in proposals with 5 or less partners), provided approval by the concerned FPO.

Please note that the following actions are considered as changes: addition, removal or replacement of a Partner (incl. subcontracted and self-financed partners). The maximum number of changes applies to "Partner", i.e. the independent legal entity participating in the Transnational RD&I project.

When applying, keep in mind that the submission system will close at 15:00 CEST of the deadline date established for Step 2. However, the CS can only ensure responses to email support requests up to 13:00 CEST.

Call for transnational research projects on Title of the call

Main project data

NB: This part will be fetched from the already submitted pre-proposal application. Changes allowed shall be requested and confirmed only by the relevant FPO involved. Any other change will be rejected.

Project short name/acronym*	(max 20 characters including spaces)
Project title*	(max 150 characters including spaces)
Project abstract	(max 4000 characters including spaces) The summary must include the a) general objectives of the project (strategic, commercial, etc.); b) scientific and/or technological aims of the project; c) relevance to the call.
Start date	(1 st quarter 2023)
Project duration (months)	The duration is 36 months
Project total costs	
Total funds requested to FPOs	

1. Administrative details

NB: This part will be fetched from the already submitted pre-proposal application. Changes allowed shall be requested and confirmed only by the relevant FPO involved. Any other change will be rejected.

You will have to provide in this section information on the coordinator and Partners involved, as well as the requested budget per Partner.

There are 2 categories of Partners:

- 1. Partners from countries (and organisations) eligible for direct funding (designated Partners 1, 2... N). Please, consider that there cannot be more than 7 partners, including one self-funded, if present.
- 2. Fully self-financed Partner from any country who bring their own secured budget. The self-funded partner cannot be the project Coordinator. No more than one self-funded project partner per consortium is allowed.

Partner data

Coordinator (Partne	Coordinator (Partner 1) or Partner 2, Partner 3 Partner N				
Please insert as ma	Please insert as many copies of this table as necessary for other Partners. Consider that there cannot be				
more than 7 partne	ers, including one self-funded, if pi	resent.			
Legal full name of					
the research	of the research				
organisation /	organisation/Company				
Company					
Researcher in charg	ge (Principal investigator):				
Family name		First name			
Title	Gender				
Phone	E-mail				
ORCID id.	d. Nationality				
(optional)					

Career Stage¹ (optional) Web site Participant Identification Code (PIC) of the organisation²	Category B: S Category C: F Category D: I	Fop grade researcher Senior researcher Recognised researche First stage researchei	Status: Priva	ate or Public?	Choose between: Private Public
Participant	Choose	Small or Medium-	Choose	Statistical Classification	
Organisation Type	between: HES, REC, PRC, PUB, OTH ³	sized Enterprise (SME status):	between: YES, NO	of Economic Activities (NACE) ⁴ :	
Registered Office			<u>, </u>		
address of the					
research					
organisation /					
company					
Street name and number					
PO Box		Postal Code		Cedex	
Town			Town		
Division /					
Department /					
Unit or					
Laboratory Street name and					
number					
Hullibel					

¹ Choose one of the following 4 options:

- Category A: the single highest grade/post at which research is normally conducted. (Example: "director of research")
- Category B: Researchers working in positions not as senior as top position (A) but more senior than newly qualified doctoral graduates (Example: "senior researcher").
- Category C: the first grade/post into which a newly qualified doctoral graduate would normally be recruited. (Examples: "researcher", "investigator" or "post-doctoral fellow").
- Category D: Either doctoral students at the IsCED level 8 who are engaged as researchers, or researchers working in posts that do not normally require a doctorate degree. (Examples: "Ph.D. students" or "junior researchers" without a Ph.D).

These categories are defined in Frascati manual from OECD https://www.oecd.org/sti/inno/frascati-manual.htm (page 249)

² 9-digit number serving as a unique identifier for organisations (legal entities) participating in EU funding programmes / procurements. If needed, one can apply for a temporary PIC on: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/participant-register. A search tool for organisations and their PICs is available on https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/participant-register-search. We suggest validating the PICs via the public available Partner Search — Organisation Profile service. This allows use to fill out some requested data inputs automatically, which is less error-prone and provides much better user experience. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/apis

³ Secondary and higher education establishments (HES); Research organisations (excluding education) (REC); Private for-profit companies (PRC); Public bodies (excluding research and education) (PUB); Other entities (OTH).

⁴ The NACE code is a Statistical Classification of Economic Activities of the organisation. You can find further information about NACE at Eurostat website https://ec.europa.eu/eurostat/web/nace-rev2 and the classification can be downloaded at https://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_CLS_DLD&StrNom=NACE_REV2&StrLanguageCode =EN&IntCurrentPage=1&StrLayoutCode=LINEAR#

PO Box		Postal code		Cedex	
Town			Country		
Employment status	s information		Choose betwe	en:	
			On permanen	t position	
			On fixed-term	position	
			If on fixed ter	m position:	
			- Duration o	of contract:	
			- Employer	Name:	
Other team member	ers involved in	the project*	·	·	
Team member 1: F	amily name, Fi	rst name,			
gender, title, phone	e, email, ORCID	id.			
Team member 2: F	amily name, Fi	rst name,			
gender, title, phone	e, email, ORCID	id.			
Team member N: Family name, First name,					
gender, title, phone	e, email, ORCID	id.			
* Dlagga include all	* Places include all the team members to be involved				a fundad or not by your

^{*} Please include all the team members to be involved in the project, would they be funded or not by your Funding Organisation. If you do not have yet this information for one team member (e.g. for a postdoc), you can indicate "to be determined"

Self-financed Partner data

Partner A				
Legal full name		Short name (acronym)		
of the research		of the research		
organisation /		organisation/Company		
Company				
Researcher in cha	arge (Principal investigator):			
Family name		First name		
Title		Gender		
Phone		E-mail		
ORCID id.		Nationality		
Career Stage	To be chosen among:			
	Category A: Top grade researcher			
	Category B: Senior researcher			
	Category C: Recognised researche	er		
	Category D: First stage researcher	•		
Web site				
Participant		Status: Private or Public?		Choose
Identification				between:
Code (PIC) of				Private
the				Public
organisation ⁵				

⁵ 9-digit number serving as a unique identifier for organisations (legal entities) participating in EU funding programmes / procurements. If needed, one can apply for a temporary PIC on: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participant-register. A search tool for organisations and their PICs is available on https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participant-register-search. Organisation Profile service. This allows use to fill out some requested data inputs automatically, which is less error-prone and provides much better user experience. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/apis

Participant	Choose	Small or	Choose	Statistic	cal	
Organisation	between:	Medium-sized	between:	Classifi	cation	
Type	HES, REC, PRC,	Enterprise	YES, NO	of Econ	omic	
	PUB, OTH ⁶	(SME status):		Activiti	es	
				(NACE)	⁷ :	
Division /						
Department /						
Unit or						
Laboratory						
Street name						
and number						
PO Box	P	ostal code		Cedex		
Town			Country			
Employment stat	us information		Choose between:			
		On permanent position				
		On fixed-term	position			
			If on fixed tern	n position:		
			- Duration o	f contract:		
			- Funding bo	ody:		
Other team mem	bers involved in th	ne project*				
Team member 1:	Family name, Firs	t name,				_
gender, title, phone, email, ORCID id.						
Team member 2: Family name, First name,						
gender, title, phone, email, ORCID id.						
Team member N: Family name, First name,						
gender, title, phone, email, ORCID id.						
* Plagge include of	* Please include all the team members to be involved in the project, would they be funded or not by your					

^{*} Please include all the team members to be involved in the project, would they be funded or not by your Funding Organisation. If you do not have yet this information for one team member (e.g. for a postdoc), you can indicate "to be determined"

2. Topics

Please specify which topic and subtopics are addressed by your proposal. Include also an estimation of percentage of coverage.

Topic 1	Sum for topic 1
- Subtopic 1.1	(percentage)
- Subtopic 1.2	(percentage)
- Subtopic 1.3	(percentage)
Topic 2	Sum for topic 2
- Subtopic 2.1	(percentage)
- Subtopic 2.2	(percentage)

⁶ Secondary and higher education establishments (HES); Research organisations (excluding education) (REC); Private for-profit companies (PRC); Public bodies (excluding research and education) (PUB); Other entities (OTH).

⁷ The NACE code is a Statistical Classification of Economic Activities of the organisation. You can find further information about NACE at Eurostat website https://ec.europa.eu/eurostat/web/nace-rev2 and the classification can be downloaded at https://ec.europa.eu/eurostat/ramon/nomenclatures/index.cfm?TargetUrl=LST_CLS_DLD&StrNom=NACE_REV2&StrLanguageCode=EN&IntCurrentPage=1&StrLayoutCode=LINEAR#

- Subtopic 2.3	(percentage)
Topic 3	Sum for topic 3
- Subtopic 3.1	(percentage)
- Subtopic 3.2	(percentage)
- Subtopic 3.3	(percentage)

Total (it must be 100%)	100%
10 1011 (10 111100 100 = 001.5)	

Keywords	
Maximum 5 keywords related to your project	
may be entered here. Keywords help effective	
expert selection to evaluate your proposal.	

Project description

The project description must include a) state of the art, own work, previous activities of the consortium in the field; b) objectives, aims, c) relevance to the call (including theme(s)); d) concept, methods; e) explanation of the novelty of the research planned, in relation to the present state-of-the-art; f) expected results and how they lead to impact; g) Transnational added value of the research proposed; h) workplan;) exploitation and dissemination of results including open science practices, sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

NB: This part will have to be uploaded as a single pdf on the Online Submission Tool. Max. 16 pages – including title and citations – Arial font, 11pts, single spaced, margins of 1.27 cm. Footnotes are allowed, if you respect the above-mentioned layout criteria. Links and hyperlinks are allowed only for bibliographical references.

The Project Description template is available in ANNEX 1.

3. Financial data

NB: This part will be fetched from the already submitted pre-proposal application. Changes allowed shall be requested and confirmed only by the relevant FPO involved. Any other change will be rejected.

Project finances

Please note that you should indicate in this table the total costs of the project and the funding requested to your Funding Organisation and their indicative repartition between the different categories of costs, i.e. personnel (including permanent salaries depending on Funding Organisations' rules), equipment, consumables, subcontracts, travels, overheads). Please make sure to follow your Funding Organisations' rules for the determination of the eligible costs and the requested funding calculation. Please note that some Funding Organisations cannot provide a funding equal to 100% of eligible costs. For questions, contact your Funding organisation Contact Point

The column **Total costs** comprise all the costs related to the project independently of national funding rules. You have to indicate here all the costs of the project.

The column Funding request comprises the part of the costs that you will request from your Funding Organisation.

The column Own funding will be filled in automatically by Online Submission Tool, it includes all the expenses which are not covered by the Funding organisation (either because the funding level is lower than 100% and/or some expenses are not eligible for funding and/or are provided in-kind). The Own funding is equal to the difference between the Total cost and the Funding request.

Please, include one table like the following one for each partner.

Partner 1					
Name	put the short name	Countr	У		
Funding organisation(s) to which you are applying for funding ⁸ To be selected on the list of Fund				selected on the list of Funding	
			organi	zations	

items	Total cost (in Euro including VAT) depending on national rules)	Funding requested (in Euro, including VAT depending on national rules) ⁹	Own funding (equal to the difference between total cost and funding requested)
Personnel			Calculated by Online Submission Tool
Equipment			Calculated by Online Submission Tool
Consumables			Calculated by Online Submission Tool
Subcontracting ¹⁰			Calculated by Online Submission Tool
Travel			Calculated by Online Submission Tool
Other Costs			Calculated by Online Submission Tool
Overhead			Calculated by Online Submission Tool
Total	Calculated by Online Submission Tool	Calculated by Online Submission Tool	Calculated by Online Submission Tool

Total person months	To be filled in by coordinator/partners

Warning

- The workload distribution within a consortium must be balanced, and no partner (including a self-funded partner) should have more than 50% of person months.
- Partners from the same country shall not have, altogether, more than 50 % of person months

⁸ Please indicate to which Funding Organisation you are requesting funds

⁹ Please make sure that VAT is eligible according to national/regional legal framework and Funding Organisations' rules. If not, please do not include VAT.

¹⁰ Indicate here the total budget and requested budget for your subcontracted Partners and/or any other subcontracting costs.

In case of not accomplishment with the above-mentioned rules, the Online Submission Tool will block your proposal submission

WORKLOAD DISTRIBUTION

This table will be automatically filled in with data included by partners. This table is only visible on the proposal preview (Downloadable PDF)

Partner 1	Person Months	Workload percentage
Partner 2		
Partner 3		
	Tot PM	100%

Finance comments

please enter a brief description of mayor costs items and short justification (personnel, equipment, consumables, subcontracts, travel expenses, other costs). For overhead costs, national regulations may apply.

(max 1000 characters i	ncludina snaces)	
(IIIax 1000 characters in	icidaling spaces,	

For the self-financed Partner, please indicate shortly how its participation to the project will be funded. Please note that a Letter of Commitment will be required as a mandatory document in the full proposal application.

Self-financed Partner A	
Name	
Country	
The Partner will be funded through	

Consortia with self-funded partners must upload the Letter of commitment. Sample available for download. UPLOAD LETTER OF COMMITMENT on the available resources of self-funded partner

4. Other Info

NB: This part will be fetched from the already submitted pre-proposal application. Applicants that may want to fine tuning this section are allowed to do so.

Do No Significant Harm (DNSH) assessment

The Do no significant harm principle was introduced in the European Green Deal to ensure that the research and innovation activities do not make directly or indirectly a significant harm to any of the six environmental objectives, according to the EU Taxonomy Regulation (EU) 2020/852You can find more information on what is considered as doing significant harm to the above objectives in the following note: https://ec.europa.eu/info/sites/default/files/c2021_1054_en.pdf.

The applicant shall self-assess the DNSH filling in the following table:

Please indicate which of the following environmental objectives require further	YES	NO	Justification if NO has been selected
evaluation according to the DNSH principle			
Climate change mitigation			
Climate change adaptation			
The sustainable use and protection of			
water and marine resources			
The circular economy, including waste prevention and recycling			
Pollution prevention and control to air, water or land			
The protection and restoration of			
biodiversity and ecosystems			

Only if the answer is YES for an environmental objective, a substantive DNSH assessment is needed. In that case, please fill the corresponding row in the table below.

Questi	ions	NO	Substantive justification
expect	te change mitigation: Is the measure ted to lead to significant GHG ons? 11		
expect impact expect	te change adaptation: Is the measure ted to lead to an increased adverse to fit the current climate and the ted future climate, on the measure or on people, nature or assets?		
and m	stainable use and protection of water arine resources: Is the measure ted to be detrimental: to the good status or the good ecological potential of bodies of water, including surface water and groundwater; or to the good environmental status of marine waters?		
includ	ansition to a circular economy, ing waste prevention and recycling: Is		
the me	easure expected to: lead to a significant increase in the		
(ii)	generation, incineration or disposal of waste, with the exception of the incineration of non-recyclable hazardous waste; or lead to significant inefficiencies in the direct or indirect use of any natural resource (1) at any stage of		
	its life cycle which are not minimised by adequate measures (2); or		

¹¹ Please notice that the mitigation measures in the call announcement do not only refer to GHG emission but it has a broader meaning. In this cell please specify the mitigation measure related to GHG emission, if any.

(iii)	cause significant and long-term	
	harm to the environment in respect	
	to the circular economy (3)?	
Polluti	ion prevention and control: Is the	
measu	re expected to lead to a significant	
increa	se in the emissions of pollutants (4)	
into ai	r, water or land?	
The pr	otection and restoration of	
biodiv	ersity and ecosystems: Is the measure	
expec	ted to be:	
(i)	significantly detrimental to the good	
	condition (5) and resilience of	
	ecosystems; or	
(ii)	detrimental to the conservation	
	status of habitants and species,	
	including those of Union interest?	

- (1) Natural resources comprise energy, materials, metals, water, biomass, air and land.
- (2) For instance, inefficiencies can be minimised by significantly increasing the durability, reparability, upgradability and reusability of products or by significantly reducing resources through the design and choice of materials, facilitating repurposing, disassembly and deconstruction, in particular to reduce the use of building materials and promote the reuse of building materials. Additionally, transitioning to 'product-as-aservice business models and circular value chains with the aim of keeping products, components and materials at their highest utility and value for as long as possible. This also comprises a significant reduction in the content of hazardous substance in materials and products, including by replacing them with safer alternatives. This further includes significantly reducing food waste in the production, processing, manufacturing or distribution of food.
- (3) Please refer to Recital 27 of the Taxonomy Regulation for more information on the circular economy objective.
- (4) Pollutant means a substance, vibration, heat, noise, light or other contaminant present in air, water or land which may be harmful to human health or the environment.
- (5) In line with Article 2(16) of the Taxonomy Regulation, "'good condition' means, in relation to an ecosystem, that the ecosystem is in good physical, chemical and biological condition or of a good physical, chemical and biological quality with self-reproduction or self-restoration capability, in which species composition, ecosystem structure and ecological functions are not impaired".

Ethics self-assessment

NB: This part will be fetched from the already submitted pre-proposal application. Applicants that may want to fine tuning this section are allowed to do so.

The applicant shall self-assess the respect of the ethics principles answering to the following questionnaire:

1. HUMAN EMBRYONIC STEM CELLS AND HUMAN EMBRYOS	Y/N	If yes, please detail and indicate how you plan to deal with this ethic issue.
Does this activity involve Human Embryonic Stem Cells (hESCs)?	Y/N	
If yes, will they be directly derived from embryos within this project?	Y/N	

If yes, are they previously established cells lines? If yes, are the cell lines registered in the European registry for human embryonic stem cell lines? Does this activity involve the use of human embryos? If yes, will the activity lead to their destruction? 2. HUMANS Does your research involve human participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a clinical trial? Joes this activity involve the use of human cells or tissues? Y/N HUMAN CELLS / TISSUES Does this activity involve the use of human cells or tissues?		
European registry for human embryonic stem cell lines? Does this activity involve the use of human embryos? If yes, will the activity lead to their destruction? Y/N 2. HUMANS Does your research involve human participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? John Studen St		Y/N
embryos? If yes, will the activity lead to their destruction? 2. HUMANS Does your research involve human participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Jes, is it a clivity involve the use of human cells Jes, is it a clivity involve the use of human cells Jes, is it a clivity involve the use of human cells Jes, is it a clivity involve the use of human cells Jes, is it a clivity involve the use of human cells Jes, interventions Jes, interventio	European registry for human embryonic stem	Y/N
Does your research involve human participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	1	Y/N
Does your research involve human participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	If yes, will the activity lead to their destruction?	Y/N
participants? If yes, are they volunteers for nonmedical studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? J/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	2. HUMANS	
studies (e.g. social or human sciences research)? If yes, are they healthy volunteers or medical studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES	1	Y/N
studies? If yes, are they patients for medical studies? If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES	studies (e.g. social or human sciences	Y/N
If yes, are they potentially vulnerable individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N		Y/N
individuals or groups? If yes, are they children / minors? If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	If yes, are they patients for medical studies?	Y/N
If yes, are they other persons unable to give informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N		Y/N
informed consent? Does your research involve physical interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	If yes, are they children / minors?	Y/N
interventions on the study participants? If yes, does it involve invasive techniques? If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N		Y/N
If yes, does it involve collection of biological samples? Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	1	Y/N
Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	If yes, does it involve invasive techniques?	Y/N
study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products). If yes, is it a clinical trial? If yes, is it a low-intervention clinical trial? Y/N 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	_	Y/N
If yes, is it a low-intervention clinical trial? 3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced	Y/N
3. HUMAN CELLS / TISSUES Does this activity involve the use of human cells Y/N	If yes, is it a clinical trial?	Y/N
Does this activity involve the use of human cells Y/N	If yes, is it a low-intervention clinical trial?	Y/N
	3. HUMAN CELLS / TISSUES	1
	•	Y/N

If yes, are they human embryonic or foetal cells or tissues?	Y/N	
If yes, are they available commercially?	Y/N	
If yes, are they obtained within this project?	Y/N	
If yes, are they obtained from another project, laboratory or institution?	Y/N	
If yes, are they obtained from biobank?	Y/N	
4. PERSONAL DATA		
Does this activity involve processing of personal data?	Y/N	
If yes, does it involve the processing of special categories of personal data (e.g.: sexual lifestyle, ethnicity, genetic, biometric and health data, political opinion, religious or philosophical	Y/N	
If yes, does it involve profiling, systematic monitoring of individuals, or processing of large scale of special categories of data or intrusive methods of data processing (such as, surveillance, geolocation tracking etc.)?	Y/N	
Does this activity involve further processing of previously collected personal data (including use of pre-existing data sets or sources, merging existing data sets)?	Y/N	
Is it planned to export personal data from the EU to non-EU countries?	Y/N	
If yes, specify the type of personal data and coun	tries invo	olved:
Is it planned to import personal data from non- EU countries into the EU or from a non-EU country to another non-EU country?	Y/N	
If yes, specify the type of personal data and coun	tries invo	olved:
5. ANIMALS		
Does your research involve animals?	Y/N	
If yes, are they vertebrates?	Y/N	
If yes, are they non-human primates (NHP)?	Y/N	
If yes, are they genetically modified?	Y/N	
If yes, are they cloned farm animals?	Y/N	

If yes, are they endangered species?	Y/N			
6. NON-EU COUNTRIES				
Will some of the activities be carried out in non-EU countries?	Y/N			
If yes, specify the countries	1			
In case non-EU countries are involved, do the activities undertaken in these countries raise potential ethics issues?	Y/N			
If yes, specify the countries				
Is it planned to use local resources (e.g. animal and/or human tissue samples, genetic material, live animals, human remains, materials of historical value, endangered fauna or flora samples, etc.)?	Y/N			
Is it planned to import any material (other than data) from non-EU countries into the EU or from a non-EU country to another non-EU country? For data imports, see section 4.	Y/N			
If yes, specify material and countries involved:				
Is it planned to export any material (other than data) from the EU to non-EU countries? For data exports, see section 4.	Y/N			
If yes, specify material and countries involved:	1			
Does this activity involve low and/or lower-middle income countries? (if yes, detail the benefit- sharing actions planned in the self-assessment)	Y/N			
Could the situation in the country put the individuals taking part in the activity at risk?	Y/N			
7. ENVIRONMENT & HEALTH and SAFETY				
Does this activity involve the use of substances or processes that may cause harm to the environment, to animals or plants (during the implementation of the activity or further to the use of the results, as a possible impact)?	Y/N			
Does this activity deal with endangered fauna and/or flora / protected areas?	Y/N			
Does this activity involve the use of substances or processes that may cause harm to humans,	Y/N			

including those performing the activity (during the implementation of the activity or further to the use of the results, as a possible impact)?		
8. ARTIFICIAL INTELLIGENCE		
Does this activity involve the development, deployment and/or use of Artificial Intelligence? (if yes, detail in the selfassessment whether that could raise ethical concerns related to human rights and values and detail how this will be addressed).	Y/N	
11. OTHER ETHICS ISSUES		
Are there any other ethics issues that should be taken into consideration?	Y/N	
Please specify: (Maximum number of characters	allowed	: 1000)

Confirmation of submission & use of data

For information: the data provided in this proposal application form will be used to:

- communicate with you about the call and application process
- allow the funding organisations to perform an eligibility check of the applicants
- assess the competencies and complementarities of your proposal and consortia by the Evaluation Committee members and external reviewers
- award funding if your application is successful
- analyse and describe our applicant pool (the name of applicants are anonymised in our analysis)
- collect your feedbacks and improve our communications with potential future applicants in future Joint Calls

Anonymity and confidentiality will be maintained throughout processing of these data for the production of statistics. Please note that these data will be accessible to Funding Organisations participating to the call, including the ones based in non-EU or non-EEA countries. Protection of personal data and compliance with the EU's General Data Protection Regulation (2016/679) (GDPR) is however ensured.

Retention of personal data shall take an end in accordance with the *Online Submission Tool General* <u>Data</u> <u>Protection Policy</u> and Water4All <u>Privacy and Data Policy</u>.

5. CV Coordinator and Principal Investigators

NB: This part will be fetched from the already submitted pre-proposal application. Coordinator in charge cannot be changed unless the occurrence of Force Majeure. Please notice to the relevant FPOs for timely communication.

Upload a brief CV of the Coordinator and of the Principal investigator of each partner (max 2 pages each)

6. Application submission

Before submitting the application, the Coordinator declares that:

- The project applicants hereby declare, that to the best of their knowledge the research outlined in this proposal is unique in character and does not duplicate research already funded at national, regional or EU level, within nation, regional, international or EU calls.
- The applicants confirm that they are aware that failure to fulfil this condition will result in the withdraw of this proposal from the application process or the withdraw of funding from approved projects.
- The proposal is line with the guidelines to ethical aspects of the Horizon Europe Programme

The final step is to press the "Submit"-button. After that, A SUBMITTED PROPOSAL EXISTS. A submitted full-proposal can be changed and resubmitted any time until the closing date.



ANNEX 1

WATER 4 ALL

JOINT TRANSNATIONAL CALL 2022: "Management of water resources: resilience, adaptation and mitigation to hydroclimatic extreme events and management tools"

Title and acronym of the full-proposal

TEMPLATE FOR THE FULL-PROPOSAL

Instructions: the project description shall be written in maximum 16 pages – including title and citations – Arial font, 11pts, single spaced, margins of 1.27 cm. Footnotes are allowed, if you respect the above-mentioned layout criteria. Links and hyperlinks are allowed only for bibliographical references.

The project description must include:

- a. State of the art, own work, previous activities of the consortium in the field;
- b. Objectives, aims;
- c. Relevance to the call (including theme(s));
- d. Concept, methods;
- e. Explanation of the novelty of the research planned, in relation to the present state-of-the-art;
- f. Expected results and how they lead to impact:
- g. Transnational added value of the research proposed;
- h. Workplan;
- i. Project coordination and management
- j. Time schedule and working programme (use a Gantt chart or equivalent)
- k. Exploitation and dissemination of results:
 - Stakeholders' engagement
 - Open science practices, sharing and management of research outputs and Data Management approach
 - o Engagement of citizens, civil society and end users where appropriate.
- Description of changes required by FPOs as 1st step evaluation output and how they have been addressed.